Markus Mohrs

Regeneron (United States) — United States

Medicine · Health Sciences

47h-index12.0kcitations120works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(40), Immune Cell Function and Interaction(38), Immunotherapy and Immune Responses(34), T-cell and B-cell Immunology(25), Monoclonal and Polyclonal Antibodies Research(20)

Publications120 total

Human CD4 cytotoxic T lymphocytes mediate potent tumor control in humanized immune system mice
Communications Biology·2023· 14 citedOpen Access
Data from Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <i>PD-1</i> Knock-In Mice
2023Open Access
Figure S4 from Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <i>PD-1</i> Knock-In Mice
2023Open Access
Supplementary Figure S2 from Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human <i>PD-1xLAG-3</i>–Knockin Mice
2023Open Access
Supplementary Figure S4 from Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human <i>PD-1xLAG-3</i>–Knockin Mice
2023Open Access
Supplementary Figure S5 from Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human <i>PD-1xLAG-3</i>–Knockin Mice
2023Open Access
Figure S6 from Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <i>PD-1</i> Knock-In Mice
2023Open Access
Figure s1 from Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <i>PD-1</i> Knock-In Mice
2023Open Access
Supplementary Figure S4 from Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human <i>PD-1xLAG-3</i>–Knockin Mice
2023Open Access
Supplementary Figure Legends from Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <i>PD-1</i> Knock-In Mice
2023Open Access
Table S1 from Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <i>PD-1</i> Knock-In Mice
2023Open Access
Figure S4 from Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <i>PD-1</i> Knock-In Mice
2023Open Access
Data from Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <i>PD-1</i> Knock-In Mice
2023Open Access
Table S1 from Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <i>PD-1</i> Knock-In Mice
2023Open Access
Figure S3 from Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <i>PD-1</i> Knock-In Mice
2023Open Access
Supplementary Figure S3 from Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human <i>PD-1xLAG-3</i>–Knockin Mice
2023Open Access
Supplementary Figure S3 from Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human <i>PD-1xLAG-3</i>–Knockin Mice
2023Open Access
Supplementary Figure S1 from Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human <i>PD-1xLAG-3</i>–Knockin Mice
2023Open Access
Figure S7 from Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <i>PD-1</i> Knock-In Mice
2023Open Access
Supplementary Materials and Methods from Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human <i>PD-1xLAG-3</i>–Knockin Mice
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Katja Mohrs(15), Frank Brombacher(12), Richard M. Locksley(11), Edward J. Pearce(7), Irah L. King(6), Georgia Perona‐Wright(6), Daniel B. Stetson(4), André Gessner(4), Lawrence L. Johnson(4), David L. Woodland(4), Christoph Hölscher(3), R. Lee Reinhardt(3), Kanade Shinkai(3), Justin J. Taylor(3), Helmut Haas(3), Gabriele Schramm(3), Gabriele Köhler(3), David P. Harris(3), Frances E. Lund(3), Jacob E. Kohlmeier(3)